基于钆塞酸增强MRI深度学习分析预测晚期慢性肝病失代偿与死亡
本研究纳入280例接受钆塞酸增强肝胆期MRI的晚期慢性肝病患者,用深度学习自动测量肝脏-脾脏信号强度比(LS-SIR)和体积比(LS-VR)及其1年变化率,采用竞争风险分析评估其与肝失代偿及肝相关死亡或移植的关联。在代偿期晚期慢性肝病患者中,基线LS-SIR、LS-VR及ΔLS-VR与肝失代偿独立相关,ΔLS-VR亦为肝相关死亡或移植的独立预测因子。作者认为这些MRI指标可作为晚期慢性肝病的预后标志物。
要点
- 深度学习可自动测量肝胆期MRI的肝脏-脾脏信号强度比与体积比,用于晚期慢性肝病预后评估。
- 代偿期晚期慢性肝病患者中,基线LS-SIR(sHR 0.81)和LS-VR(sHR 0.71)与肝失代偿独立相关。
- ΔLS-VR可独立预测代偿期(sHR 0.46)和失代偿期(sHR 0.61)患者的肝相关死亡或移植。
核心结论
- 钆塞酸增强肝胆期MRI经深度学习自动获得的MRI指标可作为晚期慢性肝病患者的预后标志物。
研究设计与样本
- 前瞻性队列研究,纳入2011年11月至2012年8月在一家三级医疗中心因肝细胞癌监测接受钆塞酸增强MRI的280例患者(男153例,平均年龄57±7.95岁),基线及1年随访MRI。
关键影像表现/征象
- 肝胆期图像上使用深度学习算法自动测量肝脏-脾脏信号强度比(LS-SIR)和肝脏-脾脏体积比(LS-VR)。
- 计算1年随访时LS-SIR和LS-VR的百分比变化(ΔLS-SIR和ΔLS-VR)。
诊断标准与关键数值
- 代偿期晚期慢性肝病患者中,基线LS-SIR与肝失代偿独立相关(sHR 0.81,p=0.034)。
- 代偿期晚期慢性肝病患者中,基线LS-VR与肝失代偿独立相关(sHR 0.71,p=0.01)。
- 调整基线变量后,ΔLS-VR预测肝失代偿(sHR 0.54,p=0.002)。
- 代偿期晚期慢性肝病患者中,ΔLS-VR独立预测肝相关死亡或移植(sHR 0.46,p=0.026)。
- 失代偿期晚期慢性肝病患者中,ΔLS-VR独立预测肝相关死亡或移植(sHR 0.61,p=0.023)。
临床应用与阅片要点
- 作者认为,深度学习自动获得的肝胆期MRI指标可用于晚期慢性肝病患者的预后评估。
- 原文未据此给出关于日常阅片和报告的具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aimed to evaluate the usefulness of quantitative indices obtained from deep learning analysis of gadoxetic acid-enhanced hepatobiliary phase (HBP) MRI and their longitudinal changes in predicting decompensation and death in patients with advanced chronic liver disease (ACLD).
MATERIALS AND METHODS: We included patients who underwent baseline and 1-year follow-up MRI from a prospective cohort that underwent gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance between November 2011 and August 2012 at a tertiary medical center. Baseline liver condition was categorized as non-ACLD, compensated ACLD, and decompensated ACLD. The liver-to-spleen signal intensity ratio (LS-SIR) and liver-to-spleen volume ratio (LS-VR) were automatically measured on the HBP images using a deep learning algorithm, and their percentage changes at the 1-year follow-up (ΔLS-SIR and ΔLS-VR) were calculated. The associations of the MRI indices with hepatic decompensation and a composite endpoint of liver-related death or transplantation were evaluated using a competing risk analysis with multivariable Fine and Gray regression models, including baseline parameters alone and both baseline and follow-up parameters.
RESULTS: Our study included 280 patients (153 male; mean age ± standard deviation, 57 ± 7.95 years) with non-ACLD, compensated ACLD, and decompensated ACLD in 32, 186, and 62 patients, respectively. Patients were followed for 11-117 months (median, 104 months). In patients with compensated ACLD, baseline LS-SIR (sub-distribution hazard ratio [sHR], 0.81; p = 0.034) and LS-VR (sHR, 0.71; p = 0.01) were independently associated with hepatic decompensation. The ΔLS-VR (sHR, 0.54; p = 0.002) was predictive of hepatic decompensation after adjusting for baseline variables. ΔLS-VR was an independent predictor of liver-related death or transplantation in patients with compensated ACLD (sHR, 0.46; p = 0.026) and decompensated ACLD (sHR, 0.61; p = 0.023).
CONCLUSION: MRI indices automatically derived from the deep learning analysis of gadoxetic acid-enhanced HBP MRI can be used as prognostic markers in patients with ACLD.
引用
- Heo S, Lee SS, Kim SY, et al. Prediction of Decompensation and Death in Advanced Chronic Liver Disease Using Deep Learning Analysis of Gadoxetic Acid-Enhanced MRI. Korean J Radiol. 2022. PMID: 36447415. doi:10.3348/kjr.2022.0494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。